Waldencast Closes 2024 with Double-Digit Growth and Fresh Credit Facility

THE WHAT? Waldencast has released its fourth-quarter and full-year 2024 earnings, reporting double-digit net revenue growth and an updated US$205m credit facility. The results reflect strong performances from core brands Obagi Medical and Milk Makeup, alongside an extension of the company’s debt maturity profile.

THE DETAILS 

• Financial Performance: Q4 net revenue came in at US$72.1m, a 29.4% comparable net revenue increase, while Q4 adjusted EBITDA reached US$11.2m – double the same period last year. Full-year net revenue rose to US$273.9m, reflecting a 27.5% jump in comparable growth.
• Obagi Medical: The brand’s professional skincare line posted revenue of US$42.2m in Q4, driven by expanding distribution channels and higher marketing spend.
• Milk Makeup: Achieved US$29.9m in Q4 revenue, boosted by product launches and broader retail rollout, including a spring 2025 launch across more than 600 Ulta Beauty locations.
• Credit Facility: The company secured a new US$205m five-year loan arrangement, replacing its prior facility to enhance financial flexibility and extend debt maturity.

THE WHY? Waldencast’s operational focus on recognized beauty and wellness brands, combined with channel expansion and new product releases, aligns with ongoing consumer demand in cosmetics and personal care. The additional capital and improved debt structure are meant to support further growth opportunities in a competitive market.

The post Waldencast Closes 2024 with Double-Digit Growth and Fresh Credit Facility appeared first on Global Cosmetics News.